

Protocol

RepliTope™ Antigen Collection HIV Ultra

Ready-to-use peptide microarrays

Revision 1.4

Contact us:	Product Use & Liability
<p>InfoLine: +49-30-6392-7878 Order per fax: +49-30-6392-7888 or e-mail: peptide@jpt.com www: www.jpt.com</p> <p>JPT Peptide Technologies GmbH Volmerstrasse 5 12489 Berlin GERMANY</p>	<p>THESE PRODUCTS ARE FOR EXPERIMENTAL LABORATORY USE ONLY AND NOT INTENDED FOR HUMAN OR HOUSEHOLD USE. Only qualified personnel should handle these chemicals. Furthermore, JPT Peptide Technologies stresses that missing hazard warnings do not mean that the relevant product is harmless. In regard to classification the products are only for research purposes. JPT Peptide Technologies cannot be made responsible for damages arising from misuse of any product. JPT Peptide Technologies makes no warranty of any kind, expressed or implied, which extends beyond the description of the product in this brochure, except that the material will meet our described specifications at the time of delivery. JPT Peptide Technologies makes no guarantee of results and assumes no liability for injuries, damages or penalties resulting from product use, since the conditions of handling and use are beyond our control.</p>

 **Table of contents**

1	INTRODUCTION	3
2	LIST OF COMPONENTS	4
3	STORAGE AND HANDLING	5
3.1	Storage of RepliTope™ Peptide Microarray Slides	5
3.2	Handling of RepliTope™ Peptide Microarray Slides	5
4	GENERAL CONSIDERATIONS	6
4.1	Experimental basics	6
4.2	Peptide microarray layout	7
5	EXPERIMENTAL PROTOCOLS	8
5.3	Additional materials and solutions required	9
5.4	Additional hardware and software	9
5.5	General principles for incubation	10
5.5.1	Microarray incubation using microarray-chip-sandwich	11
5.5.1.1	Preparation of the slide-environment for easy handling	12
5.5.2	Fully automated microarray processing station	14
6	NOTES / TROUBLESHOOTING	15
7	ANNOTATION	17
7.1	Index	17
7.2	Protein bitstring	17
7.3	Position as mapped onto HXB2 sequence	18
7.4	Clade bitstring	18
7.5	Protein name	19
7.6	Position(s) in LANL alignment	19
8	SERVICE	20
9	RELATED PRODUCTS	20

1 Introduction

Antibody-antigen interactions are key events in immunology. Therefore, the identification of epitopes or immunodominant regions in antigens represents an important step in the characterization of antibodies. One of the most efficient ways to identify such epitopes is incubation of a collection of antigen-derived peptides displayed on glass slides (RepliTope™ Peptide Microarrays) with antibodies of interest. The *human immunodeficiency virus* (HIV) is a retrovirus of the *Lentiviridae* family. Infection with the virus causes the *acquired immunodeficiency syndrome* (AIDS), a disease of the human immune system still with dramatic effects for the patient. According to the World Health Organization (WHO), “HIV is one of the leading infectious killers, claiming more than 25 million lives over the past three decades”. JPT Peptide Technologies’ *RepliTope™ Antigen Collection HIV Ultra* peptide microarrays represent a tool for rapid screening of protein-peptide interactions. 15-meric purified peptides displayed on glass slides are chemoselectively and covalently bound, enabling effective interaction with binding partners. The peptides span the immunogenic regions of the HIV proteome, combining overlapping peptides through the full length sequence of HIV gag p17 and p24, tat, nef and env as well as the remaining immunogenic regions of the HIV proteome covering at least one sequence of each of the 7 most frequent clades (A,B,C,D,G, CRF1,CRF2) of HIV 1. The coverage for all available sequences (LANL, 2009) is for ENV 57%, GAG 72%, NEF 62% and TAT 46%. This extensive collection consists of 6758 15-meric peptides displayed on one microarray.

The high-density high-content *RepliTope™ HIV Ultra* peptide microarrays can tackle the tremendous sequence diversity of HIV and deliver information on clade-specific antibody response. This enables monitoring of humoral immune response in HIV patients independent of geographical origin and to study a broad range of different vaccines. Upon incubation with your protein, antibody or sample of interest, the binding event can be detected by reading fluorescence intensity. For this purpose, either directly labeled proteins or labeled secondary antibodies can be used.

2 List of components

Component	Quantity
<i>RepliTope™ Antigen Collection HIV Ultra</i> peptide microarrays	Glass slide displaying peptides in three identical sub arrays. Each peptide is deposited 1x per subarray
Blank slides engraved with “ <i>Blank</i> ”	One blank slide per <i>HIV Ultra</i> peptide microarray.
Spacers	Vials containing 20 spacers each.
Product Documentation	Relevant data files (peptide list as table, protocols as pdf-file and sequence info as gal-file).

3 Storage and handling

3.1 Storage of RepliTope™ Peptide Microarray Slides

- Optimal storage conditions for peptide microarray slides are in a cool (approx. 4°C / 39°F), dark and dry environment.
- Peptide microarrays are stable for at least 18 months when stored at 4°C (39°F).
- Do not freeze the peptide microarrays.

3.2 Handling of RepliTope™ Peptide Microarray Slides

- Always handle the peptide microarrays with care.
- Never touch the peptide microarray slide surface.
- Never wipe or touch the surface of the peptide microarray slide with a cloth.
- Always wear laboratory gloves when handling peptide microarray slides.
- Hold peptide microarray slides at the end, which carries the engraved data label. This label provides a unique identification of the array.
- Take care when dispensing solutions onto the slide surface. Make sure not to touch the surface with pipette-tips or dispensers.
- Inappropriate chemicals may destroy the chemical bonding of the peptides to the glass surface. Never use chemicals with corrosive activity. Avoid usage of strong alkaline or acidic solutions.
- Avoid dust or other particles during each step of the experiment. Dust, particles and resulting scratches will cause artifacts during the final signal readout.
- Preferably filter all solutions for the washing steps through 0.2 µm particle filters before use.


**READ THE ENTIRE PROTOCOL BEFORE STARTING YOUR EXPERIMENTS!
CAREFULLY NOTE THE HANDLING AND STORAGE CONDITIONS OF JPT'S PEPTIDE
MICROARRAYS.**

**PLEASE CONTACT JPT PEPTIDE TECHNOLOGIES' TECHNICAL SERVICES FOR
ASSISTANCE IF NECESSARY.**

4 General considerations

4.1 Experimental basics

The JPT Peptide Technologies' *RepliTope™ Antigen Collection HIV Ultra* peptide microarray comprises peptides derived from all available sequences (LANL, 2009). The deposited molecules represent overlapping peptides through the full length sequence of HIV gag p17 and p24, tat, nef and env as well as the remaining immunogenic regions of the HIV proteome covering at least one sequence of each of the 7 most frequent clades (A,B,C,D,G,CRF1,CRF2) of HIV 1. The coverage for all available sequences is for ENV 57%, GAG 72%, NEF 62% and TAT 46%. For principle of epitope detection see Figure 1. The peptides are chemoselectively and covalently linked to the glass surface via the C-terminus. An optimized hydrophilic linker is inserted between the glass surface and the antigen derived peptide to avoid false negatives caused by sterical hindrance.



JPT's *RepliTope™ HIV Ultra* peptide microarrays are devices for the investigation of immune monitoring; humoral immune response; seromarker discovery; antibody epitope discovery; binding experiments.

After incubation of the peptide microarray with human patient serum, bound antibodies can be detected using fluorescently labeled anti-human-IgG antibodies.

Resulting antibody signatures represent unique insights into the individual humoral immune status.

Figure 1: General principle of epitope detection using overlapping peptide scans.

JPT's *RepliTope™ HIV Ultra* peptide microarrays are delivered in a pre-treated form minimizing unspecific binding of your target antibody or protein to the slide surface. Therefore, no blocking step is needed.

4.2 Peptide microarray layout

Please refer to the gal-file provided with the product documentation for the identity and location of the spots on the microarray surface. The side of the slide with the engraved label is the surface displaying the peptides. The gal-file can be opened using microarray evaluation software-modules capable of evaluating high-density microarray slides. Since gal-files are tab-separated text files, they can be processed with software modules such as Microsoft Editor (Notepad) or Microsoft Excel. A schematic layout of the peptide microarray is shown in Figure 2. The peptides are printed in three identical sub arrays on the microarray. This enables efficient intra-chip reproducibility tests. Each subarray is printed in individual blocks.




Figure 2: Exemplary view for a microarray slide with three 18 x 18 mm sub arrays (left) and a subarray consisting of 16 individual blocks (right).

5 Experimental protocols

Note: The following procedure is given as a guideline only. The optimal experimental conditions will vary depending on the investigated sample and instruments used and can, therefore, not be predetermined. The optimal experimental conditions must be established by the user. No warranty or guarantee of performance using this procedure with your target antibody or serum can be made or is implied.

The *RepliTope™ HIV Ultra Peptide Microarray* is designed as a ready-to-use product. There is no need to perform blocking steps on the slide surface prior to incubation with the target antibody or protein. However, in case of incubations with blood sera or plasma, JPT recommends to include an additional blocking step prior to incubation with patient sample.

Please refer to the gal-files provided with the product documentation for the identity and location of the spots on the peptide microarray surface. The side of the slide displaying the peptides is marked with the engraved lot number.

5.3 Additional materials and solutions required

Component	Recommendations / Remarks
Blocking reagent / Assay Buffer	JPT recommends usage of Superblock T20 (Thermo/Pierce (#37536)) as blocking and dilution buffer
Primary antibody:	Final concentration of about 1-10 µg/mL.
Proteins / enzymes:	For analysis of e.g. HIV binding or modifying components, JPT recommends a final concentration of 10 µg/mL or above.
Blood sera or plasma solution:	Final sample dilution of 1:100 to 1:500 in blocking reagent or assay buffer.
Secondary antibody:	Fluorescently labeled secondary antibody. JPT recommends Cy5 or related dyes and a final conc. of about 1 µg/mL. Blue and green dyes are not recommended due to background issues.
Tris buffered saline:	1x TBS-Buffer + 0.1% Tween20 (TBS-T)
De-ionized water:	For final washing steps of the microarrays.

5.4 Additional hardware and software

Component	Recommendations / Remarks
Automated incubation/ hybridization station	Tecan Hybridization Station HS4X00 <i>Note: Alternatively a microarray incubation sandwich can be used. Please refer to point 5.5.1 for further details.</i>
Microarray centrifuge	Or access to a stream of nitrogen to dry the microarray slides.
Fluorescence scanner/imager	Capable of excitation of appropriate fluorophore moiety and with a pixel size of at least 10 µm.
Software	Allowing quantification of the image and the assignment of signal intensities to individual peptides using the enclosed gal-file.

5.5 General principles for incubation

I. INCUBATION	WITH PRIMARY ANTIBODY / ANALYTE	2 hrs
	@30°C (86°F)	
	<i>Note: Final assay volume of the chip sandwich ~ 300 µl !</i>	
II. DISASSEMBLING	in TBS-T	
III. WASHING	with TBS-T	5x 3-4 min
IV. INCUBATION	WITH SECONDARY ANTIBODY	
	@30°C (86°F)	30-45 min
V. WASHING	with TBS-T	5x 3-4 min
	with de-ionized H ₂ O	5x 3-4 min
VI. SLIDE DRYING	Using microarray centrifuge / by blowing a gentle stream of nitrogen on the microarray surface	
VII. IMAGING	Fluorescence scanning	
	<i>Note: Scanning resolution = 10 µm pixel size!</i>	
VIII. DATA ANALYSIS	Determination of signal intensities of each peptide spot.	
	Bioinformatic evaluation of data.	

5.5.1 Microarray incubation using microarray-chip-sandwich

To create a simple incubation chamber, two slides, one displaying the peptides and another slide (*Blank-slide*) without peptides, are assembled according to Figure 3 in a sandwich like format. Alternatively, two peptide carrying slides can be assembled to form an incubation chamber allowing further quality control of the experiment. Please make sure that in such a case the two peptide-displaying sides are facing each other. The two slides are separated by two spacers.




Figure 3: Microarray incubation using microarray-chip-sandwich.

a) For assembly of "Chip-Sandwich" two plastic spacers are placed between the peptide displaying microarray (bottom slide) and the *Blank-slide* or second peptide displaying microarray (top slide) resulting in a defined reaction chamber.


b) Assay solution is applied via pipette tip into the reaction chamber formed by the two slides. Capillary forces will soak-in the solution without formation of bubbles.

c) Top microarray is shifted resulting in overlaying ends of the glass slides. This arrangement enables convenient disassembly after the incubation step.


The sample has to be applied in between the two slides. Therefore, the top slide is shifted about 1 mm in relation to the bottom side. If the pipette tip is adjusted on the position directly over the uncovered bottom slide the capillary forces allow proper distribution of the sample solution without formation of bubbles.

5.5.1.1 Preparation of the slide-environment for easy handling

II. WET-CHAMBER ASSEMBLY




III. PLACEMENT OF THE PEPTIDE MICROARRAY SLIDE SUPPORT PLATE FACING UPWARD



Engraved label has to be readable from top.



IV. PLACEMENT OF ENCLOSED SPACERS ON BOTH ENDS OF THE MICROARRAY



V. ASSEMBLING OF THE MICROARRAY SANDWICH



See also 5.5.1. If two peptide microarrays are used make sure that peptide displaying sides are facing each other.




VI. PREPARATION OF FINAL ASSAY SOLUTION CONTAINING TARGET ANTIBODY/ANALYTE

Approx. 300 μ L if enclosed spacers are used.



VII. PIPETTING OF THE COMPLETE VOLUME INTO MICROARRAY CHIP SANDWICH




Capillary forces will suck the solution in between the two slides. Avoid air bubbles within the sandwich.



Make sure not to touch the microarray with the pipette tip. Scratches and marks on the surface may destroy the deposited microarray and will cause artifacts!




VIII. ADJUSTMENT OF THE PEPTIDE MICROARRAY SANDWICH



As described in point 5.5.1 and Figure 3.



IX. CLOSING OF THE PETRI-DISH WITH A MATCHING COVER TO CREATE AN INCUBATION CHAMBER.



5.5.2 Fully automated microarray processing station

All peptide microarrays produced by JPT have an identical layout concerning active area and spotted surface. Although the content of the microarrays varies the overall layout and dimensions are the same.



Please check with the manufacturer of your microarray processing station for compatibility with the required liquids. Most microarray processing stations are sensible towards strong acids and organic solutions. Protocols have to be adapted to prevent permanent damage to your device.

All peptide microarrays produced by JPT are adjusted to fit in common fully automated microarray processing systems. JPT recommends using Tecan HS4X00 Hybridization systems.

Protocols and procedures for using Tecan HS4X00 systems can be provided by JPT if necessary.

6 Notes / Troubleshooting



JPT does not recommend use of fluorescently labeled primary or secondary antibodies in microarray sandwich-like incubations. Instead microarrays should be washed in solutions containing fluorescently labeled antibodies since the resulting background will be decreased to improved signal-to-noise ratio.

Comments and Suggestions

- | | |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Additional blocking step | <ul style="list-style-type: none">• Is not recommended by JPT in case of antibody incubations.• In case of incubations with blood sera or plasma, JPT recommends to include an additional blocking step prior to incubation with patient sample. |
| Artifacts | <ul style="list-style-type: none">• Avoid dust or other particles during each step of the experiment.• Dust particles and resulting scratches will cause artifacts during the final signal readout. |
| High background signals | <ul style="list-style-type: none">• Carefully adjust the final dilution of your labeled secondary antibody.• Microarray technology is very sensitive. Usage of secondary antibody in a higher dilution as proposed by the manufacturer might be necessary.• Generally, the antibody concentration of 1 µg/mL was found working well in most cases. Depending on the nature of the secondary antibody, increased concentrations may yield high background signals caused by unspecific binding to the slide surface.• If the signals within the peptide spots are saturated, higher dilution rates of antibody or changing of parameters of your fluorescence scanner are recommended. |

- Direct fluorescently labeled proteins sometimes tend to induce background signals via unspecific binding to the slide surface. Changing of buffer conditions in the incubation step can reduce background signals very efficiently. Additional washing steps can reduce non-specific binding.
- Do not allow the slides to dry at anytime before the final drying step.
- Scanning parameters should be adapted to signal intensities of the features.

Unspecific signals

- Control incubations using labeled secondary antibody alone should be performed in parallel to the actual experiment to ensure that found signals are not caused by non-specific binding of the secondary antibody to the immobilized peptides.

Little or no signals after fluorescence readout

- During the incubation step with fluorescently labeled secondary antibody, protect the slides from light!
- Change the settings and parameters of your fluorescence scanner to improve sensitivity of scanning.
- Avoid any fluorescent impurities/contaminations inside your assay or wash solutions.
- Check for such impurities through incubation and washing a *Blank*-slide with the same solutions followed by imaging.

8 Service

Contact our customer support (peptide@jpt.com) for full service.

- Incl. *RepliTope™ Antigen Collection HIV Ultra* peptide microarrays and all reagents
- Assay optimization (optional)
- Performance of your analysis
- Detection
- Quantification
- Short evaluation, resulting in a list of specific substrates or optional a detailed analysis

9 Related products

For further information visit our homepage (www.jpt.com) or contact our customer support.

- *PepStar™*: customized peptide microarrays
- *PepSpots™*: customized peptide arrays on cellulose membranes